Thus, IDO-specific T cells effectively lysed IDO+ cancer cell lines of different origin, such us colon carcinoma, melanoma, and breast cancer as well as directly ex vivo enriched leukemia cells. This evidence concerns the gene IDO1 and breast cancer.